The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease

doi:10.1016/j.neurobiolaging.2007.08.019

Neurobiology of Aging

Volume 30, Issue 5, May 2009, Pages 672-681

https://doi.org/10.1016/j.neurobiolaging.2007.08.019 Get rights and content

Abstract

While cerebrospinal fluid (CSF) biomarkers are of use in the prediction and diagnosis of Alzheimer's disease our understanding of the background effects of age and the ApoE genotype is limited. Seventy-eight community-based normal volunteers (mean age 60 ± 10 years, range 36–86) were examined to determine the relationships between CSF measures of total tau (T-tau), hyperphosphorylated tau (P-tau 231), amyloid beta (Aβ42/Aβ40 ratio), and isoprostane (IP) with age and ApoE genotype. The results showed that age by ɛ4 genotype interactions were found for P-tau231 (β = 1.82; p < 0.05) and IP (β = 1.6; p < 0.05). T-tau CSF concentration increased with age. The increasing CSF concentrations of P-tau and IP in ɛ4 carriers suggest that early tauopathy and oxidative stress may be related to the increased risk for AD. The data also suggest that T-tau changes are more age dependent than Aβ changes. The evidence that P-tau231 and IP are the earliest markers for the neuronal damage related to AD awaits longitudinal study.

Introduction

Age is major risk factor for AD (Bachman et al., 1993). Neuropathology (Bennett et al., 2006) and imaging studies [for review (Glodzik-Sobanska et al., 2005)] have shown that Alzheimer pathology begins years before clinical presentation. Both neurofibrillary tangles (NFT) and amyloid plaques are present in the brains of clinically normal subjects (Knopman et al., 2003), as are volume (Rusinek et al., 2003) and metabolic losses (de Leon et al., 2001) in limbic regions in aging subjects that predict cognitive decline.

Several CSF assays have been developed to estimate in vivo tau and amyloid pathology. These have proven useful in the diagnosis of AD and in the prediction of AD from the MCI stage (Blennow et al., 2006), and for prediction of decline among normal to MCI (Fagan et al., 2007). The total CSF tau (T-tau) concentration mirrors neuronal and axonal loss (Mori et al., 1995). However, the increased CSF T-tau level is not specific for AD as levels are also elevated in other neurodegenerative diseases (Arai et al., 1997, Mollenhauer et al., 2005). Overall, CSF T-tau reflects both the normal metabolism of tau, and the non-specific release of tau following neuronal damage, whereas P-tau231 reflects abnormal tau metabolism that is specific for tangles and for AD (Mitchell and Brindle, 2003). Several isoforms for hyperphosphorylated tau (P-tau) exist, all reflecting NFT pathology (Blennow, 2004). Meta-analysis indicated a specificity (AD vs. control) of 94% for P-tau and 82% for T-tau; sensitivity was 70% and 83%, respectively. (Blennow and Vanmechelen, 2003).

The decrease in CSF Aβ42 concentration is a reliable finding in AD samples as compared to controls, with both sensitivity and specificity fluctuating around 85% (Blennow and Vanmechelen, 2003). Recent studies suggested that the Aβ42/Aβ40 ratio instead of Aβ42 increases the overall correct classification (AD patients and controls) (Lewczuk et al., 2004a, Lewczuk et al., 2004b). The changes in Aβ42 may result not only from AD but also can be a consequence of total Aβ peptides concentrations (Aβ load), The load is best estimated by Aβ40 concentration, therefore the use of Aβ42/Aβ40 is recommended (Wiltfang et al., 2007).

CSF isoprostane, a marker of oxidative stress and inflammation has been also shown to be increased in AD (Pratico et al., 2002) and to predict AD at the MCI stage (Brys et al., 2007, de Leon et al., 2007).

The apolipoprotein E (ApoE) polymorphism is the most widely accepted genetic factor increasing the risk for sporadic AD (Farrer et al., 1997). The presence of an ApoE ɛ4 allele is associated with a reduced age of clinical onset of AD, an increased extent of AD pathology in post mortem studies (Ohm et al., 1999) and altered CSF T-tau and Aβ42 biomarkers levels in AD patients (Galasko et al., 1998).

With few exeptions the effects of age and ApoE genotype on CSF levels of AD biomarkers in normal individuals have not been addressed (Peskind et al., 2006, Sunderland et al., 2004). This paper examines these relationships in cross-section for five commonly used biomarkers.

Section snippets

Participants

Seventy eight healthy subjects (mean age 60.4 ± 10.4 years, range 36–86) were recruited to participate in longitudinal research studies at the Center for Brain Health (CBH) of the New York University School of Medicine NIH-NIA funded Alzheimer's Disease Center. Volunteers were recruited through advertisement about the research program, or were the spouses and caregivers of impaired patients being evaluated at the center. Education ranged from 10 to 20 years with a mean of 16.5 ± 2 years. The study

Demographic characteristics of the ApoE groups

There were no differences between ApoE ɛ4 negative (n = 48) and ApoE ɛ4 positive (n = 30) groups for age, education, gender or GDS score. The ApoE groups also did not differ in their neuropsychological test performances (F = 1.6, df = 9.65, p > 0.05, see Table 1). The percentages of subjects using different types of drugs in two ApoE groups did not differ (see Table 2).

Only BMI showed genotype related effects with lower BMI in the ApoE ɛ4 positive group (t = 3.2, df = 1.72, p < 0.01). For lipid profile only a

Discussion

To our knowledge, this is the first report describing normal lifespan changes in multiple CSF biomarkers used for Alzheimer's disease. We examined, in normal subjects, the relationship between age and ApoE genotype for five CSF AD biomarkers. The results showed age by genotype interactions, for some analytes and for others only age effects. No CSF biomarker marker showed effect restricted to genotype. Specifically, both P-tau231 and IP showed age by ApoE genotype interactions in the direction

Disclosures

Dr. Zinkowski owns stocks and stock options in Applied NeuroSolutions, Inc. The other authors declare no conflicts of interest.

Acknowledgements

This study was supported by: NIH-NIA AG12101, AG08051, AG022374, NIH-NCRR MO1RR0096, the American Health Assistance Foundation, and the Alzheimer's Association.

References (65)

H. Arai et al.
Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology
Biochem. Biophys. Res. Commun.
(1997)
K. Blennow et al.
Alzheimer's disease
Lancet Neurol.
(2006)
K. Blennow et al.
CSF markers for pathogenic processes in Alzheimer's disease: diagnostic implications and use in clinical neurochemistry
Brain Res. Bull.
(2003)
M. Blomberg et al.
Increasing cerebrospinal fluid tau levels in a subgroup of Alzheimer patients with apolipoprotien E allele e4 during 14 months follow-up
Neurosci. Lett.
(1996)
M. Chen et al.
Platelets Are the Primary Source of Amyloid [beta]-Peptide in Human Blood
Biochem. Biophys. Res. Commun.
(1995)
L. Glodzik-Sobanska et al.
The role of quantitative structural imaging in the early diagnosis of Alzheimer's disease
Neuroimaging Clin. N. Am.
(2005)
S. Golombowski et al.
Dependence of cerebrospinal fluid Tau protein levels on apolipoprotein E4 allele frequency in patients with Alzheimer's disease
Neurosci. Lett.
(1997)
O. Hansson et al.
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study
Lancet Neurol.
(2006)
M. Jensen et al.
Increased cerebrospinal fluid tau in patients with Alzheimer's disease
Neurosci. Lett.
(1995)
R. Kohnken et al.
Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients
Neurosci. Lett.
(2000)

P. Lewczuk et al.

Neurochemical diagnosis of Alzheimer's dementia by CSF A[beta]42 A[beta]42/A[beta]40 ratio and total tau

Neurobiol. Aging

(2004)

B.F. Main et al.

Apolipoprotein E genotyping using the polymerase chain reaction and allele-specific oligonucleotide primers

J. Lipid Res.

(1991)

H. Mori et al.

Tau in cerebrospinal fluids: establishment of the sandwich ELISA with antibody specific to the repeat sequence in tau

Neurosci. Lett.

(1995)

C. Ramassamy et al.

Oxidative Insults are associated with apolipoprotein E genotype in alzheimer's disease brain

Neurobiol. Dis.

(2000)

M. Shoji et al.

Combination assay of CSF Tau, Aβ1–40 and Aβ1–42(43) as a biochemical marker of Alzheimer's disease

J. Neurol. Sci.

(1998)

T. Sunderland et al.

Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele

Biol. Psychiatry

(2004)

H.B.M. Uylings et al.

Neuronal Changes in Normal Human Aging and Alzheimer's disease

Brain Cogn.

(2002)

N. Andreasen et al.

Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study

J. Neurol. Neurosurg. Psychiatry

(1998)

J.C. Augustinack et al.

Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease

Acta Neuropatholog.

(2002)

D.L. Bachman et al.

Incidence of dementia and probable Alzheimer's disease in a general population: the Framingham Study

Neurology

(1993)

D.A. Bennett et al.

Neuropathology of older persons without cognitive impairment from two community-based studies

Neurology

(2006)

K. Blennow

CSF biomarkers for mild cognitive impairment

J. Int. Med.

(2004)

M. Blomberg et al.

Cerebrospinal fluid tau levels increase with age in healthy individuals

Dement. Geriatr. Cogn. Disord.

(2001)

C. Briani et al.

Combined analysis of CSF +|A42 peptide and tau protein and serum antibodies to glycosaminoglycans in Alzheimer's disease: preliminary data

J. Neural. Trans.

(2002)

Brys, M., Pirraglia, E., Rich, K., Rolstad, S., Mosconi, L., Switalski, R.,Glodzik-Sobanska, L., De Santi, S.,...

Buerger, K., Alafuzoff, I., Ewers, M., Pirttila, T., Zinkowski, R., Hampel, H., 2007. No correlation between CSF tau...

K. Buerger et al.

CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease

Brain

(2006)

K. Buerger et al.

Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231

Arch. Neurol.

(2002)

P.R. Burkhard et al.

Cerebrospinal fluid tau and Abeta42 concentrations in healthy subjects: delineation of reference intervals and their limitations

Clin. Chem. Lab. Med.

(2004)

R. De Caterina et al.

Low-density lipoprotein level reduction by the 3-hydroxy-3-methylglutaryl coenzyme-a inhibitor simvastatin is accompanied by a related reduction of f2-isoprostane formation in hypercholesterolemic subjects: no further effect of vitamin E

Circulation

(2002)

M.J. de Leon et al.

Prediction of cognitive decline in normal elderly subjects with 2-[18F]fluoro-2-deoxy-d-glucose/positron-emission tomography (FDG/PET)

Proc. Natl. Acad. Sci. USA

(2001)

de Leon, M.J., Mosconi, L., Li, Y., De Santi, S., Yao, Y., Tsui, W.H., Pirraglia, E., Rich, K.E., Javier, E., Brys, M.,...

Cited by (67)

Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease
2022, eBioMedicine
Phosphorylated tau (p-tau) epitopes in cerebrospinal fluid (CSF) are accurate biomarkers for a pathological and clinical diagnosis of Alzheimer's disease (AD) and are seen to be increased in preclinical stage of the disease. However, it is unknown if these increases transpire earlier, prior to amyloid-beta (Aβ) positivity as determined by position emission tomography (PET), and if an ordinal sequence of p-tau epitopes occurs at this incipient phase
We measured CSF concentrations of p-tau181, p-tau217 and p-tau231 in 171 participants across the AD continuum who had undergone Aβ ([¹⁸F]AZD4694) and tau ([¹⁸F]MK6240) position emission tomography (PET) and clinical assessment
All CSF p-tau biomarkers were accurate predictors of cognitive impairment but CSF p-tau217 demonstrated the largest fold-changes in AD patients in comparison to non-AD dementias and cognitively unimpaired individuals. CSF p-tau231 and p-tau217 predicted Aβ and tau to a similar degree but p-tau231 attained abnormal levels first. P-tau231 was sensitive to the earliest changes of Aβ in the medial orbitofrontal, precuneus and posterior cingulate before global Aβ PET positivity was reached
We demonstrate that CSF p-tau231 increases early in development of AD pathology and is a principal candidate for detecting incipient Aβ pathology for therapeutic trial application
Canadian Institutes of Health Research (CIHR), Canadian Consortium of Neurodegeneration and Aging, Weston Brain Institute, Brain Canada Foundation, the Fonds de Recherche du Québec.
β-amyloid: The known unknowns
2021, Ageing Research Reviews
Alzheimer’s disease (AD) stands out as a major disease without any form of preventative or disease modifying therapy. This is not for lack of trying. 33 phase 3 clinical trials of drugs targeting amyloid beta (Aβ) have failed to slow cognitive decline in AD. The field is at a cross-roads about whether to continue anti-Aβ therapy or more actively pursue alternative targets. With the burden of this disease to patients, families, and healthcare budgets growing yearly, the need for disease modifying AD therapies has become one of the highest priorities in all of medicine. While pathology, genetic and biochemical data offer a popular narrative for the causative role of Aβ, there are alternative explanations, and dissenting findings that, now more than ever, warrant thorough reanalysis. This review questions the major assumptions about Aβ on which therapies for AD were premised, and invites renewed interrogation into AD pathogenesis.
Apolipoprotein E and oxidative stress in brain with relevance to Alzheimer's disease
2020, Neurobiology of Disease
Citation Excerpt :
As noted above, this peptide is associated with oxidative damage in AD and MCI brains. Consistent with this assertion, examination of CSF of individuals as a function of age and APOE genotype showed that levels of phosphorylated tau and isoprostanes, the latter a marker of lipid peroxidation, were statistically correlated in ApoE4 (Glodzik-Sobanska et al., 2009). Cerebrospinal fluid in AD and MCI demonstrates a specific oxidative signature (Di Domenico et al., 2016).
Inheritance of apolipoprotein E4 (APOE4) is a major risk factor for development of Alzheimer's disease (AD). This lipoprotein, in contrast to apoE2, has arginine residues at positions 112 and 158 in place of cysteines in the latter isoform. In apoE3, the Cys at residue 158 is replaced by an arginine residue. This differential amino acid composition of the three genotypes of APOE have profound influence on the structure, binding properties, and multiple functions of this lipoprotein. Moreover, AD brain is under a high degree of oxidative stress, including that associated with amyloid β-peptide (Aβ) oligomers. Lipid peroxidation produces the highly reactive and neurotoxic molecule, 4-hydroxynonenal (HNE) that forms covalent bonds with cysteine residues (Cys) [as well as with Lys and His residues]. Covalently modified Cys significantly alter structure and function of modified proteins. HNE bound to Cys residue(s) on apoE2 and apoE3 lessens the chance of HNE damage other proteins. apoE4, lacking Cys residues, is unable to scavenge HNE, permitting this latter neurotoxic molecule to lead to oxidative modification of neuronal proteins and eventual cell death. We posit that this lack of HNE scavenging activity in apoE4 significantly contributes to the association of APOE4 inheritance and increased risk of developing AD. Apoe knock-out mice provide insights into the role of this lipoprotein in oxidative stress. Targeted replacement mice in which the mouse gene of Apoe is separately replaced by the human APOE2, APOE3, or APOE4 genes, while keeping the mouse promoter assures the correct location and amount of the human protein isoform. Human APOE targeted replacement mice have been used to investigate the notion that oxidative damage to and death of neurons in AD and its earlier stages is related to APOE genotype. This current paper reviews the intersection of human APOE genotype, oxidative stress, and diminished function of this lipoprotein as a major contributing risk factor for development of AD. Discussion of potential therapeutic strategies to mitigate against the elevated risk of developing AD with inheritance of the APOE4 allele also is presented.
APOE alters glucose flux through central carbon pathways in astrocytes
2020, Neurobiology of Disease
Citation Excerpt :
The switch to a reductive TCA cycle as opposed to oxidative, results in the generation of less reactive oxygen species. Perhaps E4 astrocytes initiate a switch to a reductive TCA cycle in order to mitigate an environment of increased oxidative stress (Glodzik-Sobanska et al., 2009; Montine et al., 1998; Ramassamy et al., 1999; Ramassamy et al., 2000). When undergoing oxidative metabolism in the TCA cycle, glutamine can be used to generate ATP via conversion to alpha-ketoglutarate and subsequently succinate.
The Apolipoprotein E (APOE) gene is a major genetic risk factor associated with Alzheimer's disease (AD). APOE encodes for three main isoforms in humans (E2, E3, and E4). Homozygous E4 individuals have more than a 10-fold higher risk for developing late-onset AD, while E2 carriers are protected. A hallmark of AD is a reduction in cerebral glucose metabolism, alluding to a strong metabolic component in disease onset and progression. Interestingly, E4 individuals display a similar regional pattern of cerebral glucose hypometabolism decades prior to disease onset. Mapping this metabolic landscape may help elucidate the underlying biological mechanism of APOE-associated risk for AD. Efficient metabolic coupling of neurons and glia is necessary for proper neuronal function, and disruption in glial energy distribution has been proposed to contribute to neuronal cell death and AD pathology. One important function of astrocytes – canonically the primary source of apolipoprotein E in the brain – is to provide metabolic substrates (lactate, lipids, amino acids and neurotransmitters) to neurons. Here we investigate the effects of APOE on astrocyte glucose metabolism in vitro utilizing scintillation proximity assays, stable isotope tracer metabolomics, and gene expression analyses. Glucose uptake is impaired in E4 astrocytes relative to E2 or E3 with specific alterations in central carbon metabolism. Using stable isotope labeled glucose [U-¹³C] allowed analyses of astrocyte-specific deep metabolic networks affected by APOE, and provided insight to the effects downstream of glucose uptake. Enrichment of ¹³C in early steps of glycolysis was lowest in E4 astrocytes (highest in E2), while synthesis of lactate from glucose was highest in E4 astrocytes (lowest in E2). We observed an increase in glucose flux through the pentose phosphate pathway (PPP), with downstream increases in gluconeogenesis, lipid, and de novo nucleotide biosynthesis in E4 astrocytes. There was also a marked increase in ¹³C enrichment in the TCA cycle of E4 astrocytes – whose substrates were also incorporated into biosynthetic pathways at a higher rate. Pyruvate carboxylase (PC) and pyruvate dehydrogenase (PDH) are the two main enzymes controlling pyruvate entry to the TCA cycle. PC gene expression is increased in E4 astrocytes and the activity relative to PDH was also increased, compared to E2 or E3. Decreased enrichment in the TCA cycle of E2 and E3 astrocytes is suggestive of increased oxidation and non-glucose derived anaplerosis, which could be fueling mitochondrial ATP production. Conversely, E4 astrocytes appear to increase carbon flux into the TCA cycle to fuel cataplerosis. Together, these data demonstrate clear APOE isoform-specific effects on glucose utilization in astrocytes, including E4-associated increases in lactate synthesis, PPP flux, and de novo biosynthesis pathways.
APOE and metabolic dysfunction in Alzheimer's disease
2020, International Review of Neurobiology
The strongest genetic risk factor for sporadic Alzheimer's disease (AD) is carriage of the E4 allele of APOE. Metabolic dysfunction also increases risk of dementia and AD. Facing a need for effective therapies and an aging global population, studies aimed at uncovering new therapeutic targets for AD have become critical. Insight into the biology underlying the effects of E4 and metabolic impairment on the brain may lead to novel therapies to reduce AD risk. An understudied hallmark of both AD patients and E4 individuals is a common metabolic impairment—cerebral glucose hypometabolism. This is a robust and replicated finding in humans, and begins decades prior to cognitive decline. Possession of E4 also appears to alter several other aspects of cerebral glucose metabolism, fatty acid metabolism, and management of oxidative stress through the pentose phosphate pathway. A critical knowledge gap in AD is the mechanism by which APOE alters cerebral metabolism and clarification as to its relevance to AD risk. Facing a need for effective therapies, studies aimed at uncovering new therapeutic targets have become critical. One such approach is to gain a better understanding of the metabolic mechanisms that may underlie E4-associated cognitive dysfunction and AD risk.
Cyclic O<inf>3</inf> exposure synergizes with aging leading to memory impairment in male APOE ε3, but not APOE ε4, targeted replacement mice
2019, Neurobiology of Aging
The etiology of late-onset Alzheimer's disease is unknown. Recent epidemiological studies suggest that exposure to high levels of ozone (O₃) may be a risk factor for late-onset Alzheimer's disease. Nonetheless, whether and how O₃ exposure contributes to AD development remains to be determined. In this study, we tested the hypothesis that O₃ exposure synergizes with the genetic risk factor APOE ε4 and aging leading to AD, using male apolipoprotein E (apoE)4 and apoE3 targeted replacement mice as men have increased risk exposure to high levels of O₃ via working environments and few studies have addressed APOE ε4 effects on males. Surprisingly, our results show that O₃ exposure impairs memory in old apoE3, but not old apoE4 or young apoE3 and apoE4, male mice. Further studies show that old apoE4 mice have increased hippocampal activities or expression of some enzymes involved in antioxidant defense, diminished protein oxidative modification, and neuroinflammation following O₃ exposure compared with old apoE3 mice. These novel findings highlight the complexity of interactions between APOE genotype, age, and environmental exposure in AD development.

View all citing articles on Scopus

View full text

The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease

Abstract

Introduction

Section snippets

Participants

Demographic characteristics of the ApoE groups

Discussion

Disclosures

Acknowledgements

Biochem. Biophys. Res. Commun.

Lancet Neurol.

Brain Res. Bull.

Neurosci. Lett.

Biochem. Biophys. Res. Commun.

Neuroimaging Clin. N. Am.

Neurosci. Lett.

Lancet Neurol.

Neurosci. Lett.

Neurosci. Lett.

Neurobiol. Aging

J. Lipid Res.

Neurosci. Lett.

Neurobiol. Dis.

J. Neurol. Sci.

Biol. Psychiatry

Brain Cogn.

Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study

J. Neurol. Neurosurg. Psychiatry

Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease

Acta Neuropatholog.

Incidence of dementia and probable Alzheimer's disease in a general population: the Framingham Study

Neurology

Neuropathology of older persons without cognitive impairment from two community-based studies

Neurology

CSF biomarkers for mild cognitive impairment

J. Int. Med.

Cerebrospinal fluid tau levels increase with age in healthy individuals

Dement. Geriatr. Cogn. Disord.

Combined analysis of CSF +|A42 peptide and tau protein and serum antibodies to glycosaminoglycans in Alzheimer's disease: preliminary data

J. Neural. Trans.

CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease

Brain

Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231

Arch. Neurol.

Cerebrospinal fluid tau and Abeta42 concentrations in healthy subjects: delineation of reference intervals and their limitations

Clin. Chem. Lab. Med.

Low-density lipoprotein level reduction by the 3-hydroxy-3-methylglutaryl coenzyme-a inhibitor simvastatin is accompanied by a related reduction of f2-isoprostane formation in hypercholesterolemic subjects: no further effect of vitamin E

Circulation

Prediction of cognitive decline in normal elderly subjects with 2-[18F]fluoro-2-deoxy-d-glucose/positron-emission tomography (FDG/PET)

Proc. Natl. Acad. Sci. USA